(Total Views: 394)
Posted On: 08/24/2018 8:11:59 PM
Post# of 154067
NetworkNewsBreaks – CytoDyn Inc. (CYDY) Developing Therapeutic Anti-Viral Agent as Potential Alternative to Current HIV Treatment Options
Biotechnology company CytoDyn (OTCQB: CYDY) remains focused on the development of its new anti-HIV treatment, PRO 140. An article discussing the company’s therapeutic anti-viral agent reads: “The development of PRO 140 is of particular interest, because it could allow people living with HIV to take just one weekly dose instead of the daily pills required by current therapies. … An antibody rather than a drug, PRO 140 works by blocking the most prevalent HIV subtype from entering healthy cells, thus protecting them from infection. Recognizing the treatment’s potential, the FDA has designated PRO 140 a fast-track candidate. To qualify for fast-track status, a treatment must be intended for a serious condition and must also show an advantage over currently available treatment options.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn (OTCQB: CYDY) remains focused on the development of its new anti-HIV treatment, PRO 140. An article discussing the company’s therapeutic anti-viral agent reads: “The development of PRO 140 is of particular interest, because it could allow people living with HIV to take just one weekly dose instead of the daily pills required by current therapies. … An antibody rather than a drug, PRO 140 works by blocking the most prevalent HIV subtype from entering healthy cells, thus protecting them from infection. Recognizing the treatment’s potential, the FDA has designated PRO 140 a fast-track candidate. To qualify for fast-track status, a treatment must be intended for a serious condition and must also show an advantage over currently available treatment options.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
